Compass Therapeutics (NASDAQ:CMPX) Hits New 12-Month High – Here’s What Happened

Compass Therapeutics, Inc. (NASDAQ:CMPX) shares hit a new 52-week high on Thursday . The stock traded as high as $6.32 and last traded at $6.3450, with a volume of 1426515 shares traded. The stock had previously closed at $5.90.

Wall Street Analysts Forecast Growth

CMPX has been the topic of a number of research reports. Raymond James Financial restated an “outperform” rating and issued a $9.00 target price on shares of Compass Therapeutics in a report on Tuesday, January 6th. Citizens Jmp began coverage on Compass Therapeutics in a research report on Wednesday, December 3rd. They set a “market outperform” rating and a $10.00 price objective on the stock. Cantor Fitzgerald began coverage on Compass Therapeutics in a report on Wednesday, December 3rd. They issued an “overweight” rating for the company. Lifesci Capital began coverage on Compass Therapeutics in a research report on Monday, October 6th. They set an “outperform” rating and a $10.00 target price on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Compass Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $12.23.

Compass Therapeutics Stock Up 7.4%

The firm has a market cap of $1.13 billion, a PE ratio of -14.07 and a beta of 1.45. The business has a 50 day simple moving average of $5.26 and a two-hundred day simple moving average of $4.10.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. Equities analysts forecast that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of CMPX. Suvretta Capital Management LLC increased its holdings in Compass Therapeutics by 97.2% during the 3rd quarter. Suvretta Capital Management LLC now owns 14,101,159 shares of the company’s stock worth $49,354,000 after purchasing an additional 6,951,666 shares during the period. Vivo Capital LLC grew its position in shares of Compass Therapeutics by 57.9% during the 3rd quarter. Vivo Capital LLC now owns 9,545,466 shares of the company’s stock worth $33,409,000 after buying an additional 3,502,000 shares in the last quarter. Balyasny Asset Management L.P. purchased a new position in shares of Compass Therapeutics during the third quarter valued at $9,892,000. Millennium Management LLC raised its holdings in shares of Compass Therapeutics by 280.4% in the third quarter. Millennium Management LLC now owns 3,237,572 shares of the company’s stock valued at $11,332,000 after acquiring an additional 2,386,367 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in Compass Therapeutics by 45.6% in the third quarter. Vanguard Group Inc. now owns 7,062,799 shares of the company’s stock worth $24,720,000 after acquiring an additional 2,212,794 shares during the period. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical?stage biotechnology company dedicated to the discovery and development of novel immuno?oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti?tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47?SIRP? pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.